Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | MGLL | Q99685 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
| ▸ | FASN | P49327 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3284280 | 0.91 | SMN1; SMN2 (0.68) | SMN1; SMN2HTTMEN1KMT2AHPGD | |
| SCHEMBL16695142 | 0.91 | SMN1; SMN2 (0.68) | SMN1; SMN2HTTMEN1KMT2AHPGD | |
| SCHEMBL9029952 | 0.88 | SMN1; SMN2 (0.82) | SMN1; SMN2HTTMEN1KMT2AACHE | |
| SCHEMBL22622323 | 0.83 | GLA (0.70) | SMN1; SMN2HTTMEN1KMT2AHPGD | |
| SCHEMBL3319143 | 0.82 | HSD17B10 (0.74) | SMN1; SMN2HTTHPGDGLAHSD17B10 | |
| SCHEMBL3319140 | 0.82 | HSD17B10 (0.74) | SMN1; SMN2HTTHPGDGLAHSD17B10 | |
| SCHEMBL4724686 | 0.82 | KMT2A (0.55) | SMN1; SMN2MEN1KMT2AHPGDTSHR | |
| SCHEMBL27812707 | 0.81 | SMN1; SMN2 (0.58) | SMN1; SMN2HTTHPGDACHEGLA | |
| SCHEMBL22622475 | 0.81 | GLA (0.72) | SMN1; SMN2HTTMEN1KMT2AHPGD | |
| SCHEMBL16695294 | 0.79 | ACHE (0.60) | SMN1; SMN2MEN1KMT2AHPGDACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050119266-A1 | Pyrrolidine and piperidine derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-02 | — | — | US | claimed |
| EP-1684744-A4 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1684744-A2 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050119266-A1 | Pyrrolidine and piperidine derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-02 | — | — | US | disclosed |
| WO-2005032472-A2 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119266-A1 | Pyrrolidine and piperidine derivatives as factor Xa inhibitors | PEPD, SERPINE1, PRSS1 | SMN1; SMN2 3597/4885HTT 2142/4885MEN1 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.